Methods and compositions of natural killer cell adoptive transfer therapy

Abstract

Disclosed are methods and compositions useful for treating patients with inflammatory, auto-immune and age related conditions. The disclosure relates to using Natural Killer cells and derivatives thereof in order to induce therapeutic benefit to patients affected by disease and conditions such as cancer, multiple sclerosis, rheumatoid arthritis, type I diabetes mellitus, thyroid autoimmune disease, psoriasis and inflammatory bowel diseases.

What is claimed: 
     
         1 . An allogenic adoptive transfer procedure for treating inflammatory bowel disease comprising:
 a) Isolating natural killer (NK) cells that are CD3 negative and CD56 positive from peripheral blood of a human donor;   b) Expanding said NK cells in vitro;   c) Intravenously infusing said NK cells into an allogenic recipient.   
     
     
         2 . The method of  claim 1  further comprising the step of cryopreserving said NK cells. 
     
     
         3 . The method of  claim 2  further comprising the step of thawing said cryopreserved NK cells prior to infusion. 
     
     
         4 . The method of  claim 1  wherein said adoptive transfer is administered to a human without any form of cancer. 
     
     
         5 . The method of  claim 1  wherein said adoptive transfer is administered to a human without any need for antiviral treatment. 
     
     
         6 . An allogenic adoptive transfer procedure for eliminating senescent peripheral blood mononuclear cells comprising:
 a) Isolating NK cells that are CD3 negative and CD56 positive from peripheral blood of a human donor;   b) Expanding said NK cells in vitro;   c) Intravenously infusing said NK cells into an allogenic recipient.   
     
     
         7 . The method of  claim 6  wherein said NK cells are CD3 negative and CD56 positive. 
     
     
         8 . The method of  claim 6  wherein said infusion is allogenic. 
     
     
         9 . The method of  claim 6  further comprising the step of cryopreserving said NK cells. 
     
     
         10 . The method of  claim 6  further comprising the step of thawing said cryopreserved NK cells prior to infusion. 
     
     
         11 . The method of  claim 6  wherein said adoptive transfer is administered to a human without any form of cancer. 
     
     
         12 . The method of  claim 6  wherein said adoptive transfer is administered to a human without any need for antiviral treatment. 
     
     
         13 . A composition comprising a population of NK cells isolated from peripheral blood that:
 a. Are expanded in vitro;   b. Are cryopreserved following expansion in vitro;   c. Are thawed following cryopreservation;   d. Are infused in an allogeneic recipient in need thereof;   e. Reduce blood plasma levels of inflammatory cytokines IFNγ, IL-6; IL-17A, IL-27, MCP-1;   f. Reduce the concentration of p16 and p21 in peripheral blood mononuclear cells.